Agilent Technologies, Inc. (NYSE:A) Shares Sold by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. lessened its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 2.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 113,259 shares of the medical research company's stock after selling 3,234 shares during the quarter. Asset Management One Co. Ltd.'s holdings in Agilent Technologies were worth $15,351,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in A. Massachusetts Financial Services Co. MA boosted its holdings in shares of Agilent Technologies by 3.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,589,874 shares of the medical research company's stock worth $2,314,784,000 after purchasing an additional 525,214 shares during the period. FMR LLC lifted its holdings in shares of Agilent Technologies by 62.2% in the 3rd quarter. FMR LLC now owns 1,287,665 shares of the medical research company's stock worth $191,193,000 after buying an additional 493,947 shares during the period. Worldquant Millennium Advisors LLC purchased a new stake in shares of Agilent Technologies in the 3rd quarter worth $49,449,000. Van ECK Associates Corp lifted its holdings in shares of Agilent Technologies by 8.7% in the 4th quarter. Van ECK Associates Corp now owns 3,235,263 shares of the medical research company's stock worth $434,625,000 after buying an additional 258,358 shares during the period. Finally, Jennison Associates LLC lifted its holdings in shares of Agilent Technologies by 63.3% in the 3rd quarter. Jennison Associates LLC now owns 586,439 shares of the medical research company's stock worth $87,075,000 after buying an additional 227,431 shares during the period.

Agilent Technologies Stock Performance

A stock traded up $2.01 during trading on Wednesday, hitting $137.21. The company had a trading volume of 1,666,743 shares, compared to its average volume of 1,679,436. The firm has a 50-day moving average price of $141.21 and a 200-day moving average price of $139.31. The firm has a market cap of $39.15 billion, a PE ratio of 31.04, a price-to-earnings-growth ratio of 3.65 and a beta of 1.07. The company has a quick ratio of 1.58, a current ratio of 2.09 and a debt-to-equity ratio of 0.57. Agilent Technologies, Inc. has a 1-year low of $124.16 and a 1-year high of $155.35.

Agilent Technologies (NYSE:A - Get Free Report) last announced its earnings results on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, beating analysts' consensus estimates of $1.41 by $0.05. The firm had revenue of $1.70 billion for the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. Agilent Technologies's quarterly revenue was up .8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.38 EPS. On average, analysts expect that Agilent Technologies, Inc. will post 5.56 earnings per share for the current year.

Insider Buying and Selling at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total value of $286,650.00. Following the transaction, the chief executive officer now directly owns 39,652 shares of the company's stock, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Analyst Upgrades and Downgrades

A has been the subject of several recent research reports. Barclays raised Agilent Technologies from an "underweight" rating to an "equal weight" rating and boosted their price target for the stock from $135.00 to $145.00 in a research report on Monday, February 10th. Wells Fargo & Company cut their price objective on Agilent Technologies from $157.00 to $155.00 and set an "overweight" rating on the stock in a report on Monday, December 9th. StockNews.com upgraded Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday, December 24th. JPMorgan Chase & Co. lowered their target price on Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 26th. Finally, Bank of America lowered their price target on Agilent Technologies from $153.00 to $150.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. Seven investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $144.38.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.